News | October 25, 2021
Biocon reports a consolidated net profit of Rs. 138.3 crore in Q2FY22
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
Key takeaways of recent quarter & conference call highlights
The company reported 4% topline growth during the quarter driven by steady revenues in the Pharmaceuticals segment and robust growth in the Contract Research and Development Services (CRDS) segment
ICICI Direct gives an update on the 12 companies that it has covered in the healthcare universe. A report
The company is eligible for 180 days of generic drug exclusivity for Lenalidomide capsules, 2.5 mg and 20 mg
Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report
According to IQVIA, US sales of Everolimus (Afinitor) tablets were approximately US $ 675 million in the 12 months ending July 2021
The issue will consist of the issuance of fresh equity shares worth up to Rs 331.60 crore and an offer for sale (OFS) of Rs 500 crore by promoters and existing shareholders
_256_384.jpg)
CLSA, a capital market and investment group organised an Investors’ Forum where five Indian pharma companies participated. Excerpts from the report
A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges
Subscribe To Our Newsletter & Stay Updated
